Developer docs
API playgroundTry for free, no card

Search company profiles

비엑스플랜트

Full company profile

uuid0042dde

Namestring
비엑스플랜트
Legal namestring
BXPLANT Co., Ltd.
Websiteurl
bxplant.co.kr
Company typeenum
Private
Founded yearint
2024
Descriptiontext

BXPLANT (비엑스플랜트) is a privately held Clinical Development and Research Organization (CDRO) and biotech scalerator founded in January 2024 and headquartered in Seongdong-gu, Seoul, South Korea. The company operates as a 'Clinical Intelligence Agency' providing full-cycle new drug and medical device development services, spanning R&D strategy, preclinical support, clinical strategy and consulting, PK/PD Modeling & Simulation (MIDD), clinical trial operations, regulatory affairs, data management and biostatistics, pharmacovigilance, and commercialization/valuation strategy. Its core technical differentiator is a Model-Informed Drug Development (MIDD) platform combining PK/PD modeling, PBPK modeling, quantitative systems pharmacology (QSP), and population PK/PD analysis to predict clinical outcomes and optimize dose selection before trials start.

BXPLANT was co-founded by former Daewoong Pharmaceutical executives Minkeun Jo (Co-CEO, business strategy) and Heesun Kim (Co-CEO, clinical development), with a leadership team drawn from Korean pharma majors including Daewoong, Hanmi, Chong Kun Dang, Samsung BioLogics, and CJ. The company generates revenue through project-based professional services engagements billed per contract, with multi-year contracts targeted in the billions of KRW per engagement. A secondary revenue stream derives from its scalerator function, in which the company provides seed capital to biotech startups from a self-funded ~2 billion KRW investment pool and earns returns through portfolio growth and exits. BXPLANT is officially registered as a CRO with KoNECT (Korea National Enterprise for Clinical Trials).

The company targets four primary customer segments: biotech ventures and bio startups (primary), pharmaceutical companies, medical device companies, and academic medical centers/research hospitals. Named clients include Woojung BIO, ARKGEN BIOSCIONS, and Protium Science, alongside a 50+ partner ecosystem. BXPLANT reports surpassing 100 billion KRW in cumulative order volume and achieving break-even within approximately two years of founding, with an IPO targeted between 2026-2028 at a 20 billion KRW annual revenue threshold.

Short descriptiontext

BXPLANT (비엑스플랜트) is a Seoul-based CDRO and biotech scalerator founded in 2024 by former Daewoong Pharmaceutical executives, providing full-cycle clinical development, MIDD-based PK/PD modeling, regulatory affairs, and seed investment services to Korean biotech ventures, pharmaceutical companies, and medical device firms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical development services, contract research organization, drug development consulting, regulatory affairs services, biotech venture acceleration
Industry2 codes
PRIMARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAEAJ
Companion Diagnostics (CDx) Development & Trial Testing Support
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Clinical Development Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1CDRO Clinical Development Services
TypeProfessional Services
Description

Full-cycle new drug development services spanning preclinical consulting, clinical strategy, regulatory affairs (RA), CMC, preclinical toxicity studies, and Phase 1-4 clinical trial execution. Services are project-based and billed per engagement.

bxplant.co.kr
2Clinical Strategy Consulting
TypeProfessional Services
Description

R&D strategy formulation, Target Product Profile (TPP) optimization, clinical development plan (CDP) design, regulatory pathway optimization, and gap analysis for biotech ventures and pharmaceutical companies. Project-based consulting fees.

bxplant.co.kr
3Investment / Scalerator Business
TypeLicensing Royalties
Description

Identifying promising biotech startups, providing seed capital alongside strategic guidance, facilitating investment attraction, and supporting scale-up through fund formation and follow-up support programs. Investment returns from portfolio company growth and exits.

bxplant.co.kr
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Pricing details1 tier
1Custom project-based engagements for biotech ventures, pharmaceutical companies, and medical device companies
ModelOtherBilling cadenceMulti-year contract
Notes

No publicly disclosed pricing. Engagements are quote-based, tailored to project scope including preclinical strategy, clinical operations, regulatory affairs, and commercialization support. Target order values in the billions of KRW.

bxplant.co.kr
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

BXPLANT is a CDRO (Clinical Development and Research Organization) and biotech scalerator that delivers full-cycle new drug and medical device development services spanning R&D strategy, preclinical-to-clinical translation via MIDD/PK-PD modeling, clinical trial design and operations, regulatory affairs, and commercialization/out-licensing support. The company also operates a scalerator model, providing seed capital and growth acceleration to promising biotech startups alongside its consulting and CRO services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Surpassed 100 billion KRW in order volume within ~2 years of establishment (2024-2026)
+3 more records
Product overview1 text field

BXPLANT operates as a Clinical Intelligence Agency and CDRO (Clinical Development and Research Organization) company providing a unified platform of consulting and clinical services spanning the full new drug and medical device development lifecycle. The portfolio is organized into four core service pillars — Development & Strategic Solutions (non-clinical R&D support, PK/PD Modeling & Simulation, Clinical Strategy & Consulting, and CPL Services), Clinical Research Services (Medical Affair & Writing, Clinical Operations, Data Management & Biostatistics, and Pharmacovigilance), Regulatory Affairs, and Commercialization & Valuation Strategy — complemented by six specialized expertise areas: Chemical Drugs & Biologics, Advanced Therapy Products (ATMP), Medical Devices, In Vitro Diagnostics, Post-Market Surveillance & Pharmacovigilance, and Clinical Performance & Evaluation. The company also functions as a Scalerator, identifying and accelerating promising bio healthcare startups through investment, open innovation, and growth support. Revenue is derived from consulting services and CRO contract execution, with the company targeting IPO between 2026-2028.

Product and service4 records
1Development & Strategic Solutions
CategoryClinical Development Consulting
Description

Tailored R&D portfolio management and asset valuation service for early development and innovation, combining non-clinical R&D support, PK/PD Modeling & Simulation, clinical strategy & consulting, and Clinical Project Lead (CPL) services. Designed for biotech ventures and pharmaceutical companies seeking to optimize go/no-go decisions, dose selection, and clinical strategy from preclinical through Phase 2 POC.

2Clinical Research Services
CategoryContract Research Organization (CRO)
Description

End-to-end CRO support for all-phase clinical trials covering Medical Affair & Writing, Clinical Operations, Data Management & Biostatistics (DM/STAT), and Pharmacovigilance & Post-Market Safety. Supports pharmaceuticals, biologics, medical devices, and IVDs across clinical and post-market phases with GCP compliance and audit/inspection readiness.

3Regulatory Affairs
CategoryRegulatory Affairs
Description

Comprehensive regulatory strategy service from IND to marketing authorization, including CTD Module authoring, global submission readiness, and lifecycle regulatory consulting. Covers conventional and expedited pathways with local and global expertise for pharmaceuticals, biologics, medical devices, and IVDs.

4Commercialization & Valuation Strategy
CategoryScalerator / Venture Acceleration
Description

Venture scalerating and growth acceleration service including portfolio assessment, venture discovery & investment, clinical development support, out-licensing strategy, and exit planning. Provides biotech startups with seed capital alongside strategic guidance, facilitating investment attraction, fund formation, and global expansion support.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership51 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-02
Description

BXPLANT serves as the strategic accelerator for the '2026 Seoul Biohub X SK Biopharm Open Innovation' program, leading the entire process of identifying and nurturing promising companies. BXPLANT integrates its clinical and strategic expertise to provide intensive support so that SK Biopharm and innovative startups can achieve tangible results. The program recruits startups within 8 years of establishment to leverage SK Biopharm's drug development expertise and research infrastructure.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-07
Description

BXPLANT and Kyungpook National University Hospital's Clinical Trial Center and Advanced Clinical Trial Center signed an MOU for strategic cooperation in clinical trial and clinical development. The partnership provides BXPLANT's CDRO-based services (clinical development strategy, trial design and operations, project management) alongside the hospital's medical staff, patient recruitment networks, and clinical infrastructure. The goal is to enable global-level clinical trial performance outside the Seoul metropolitan area and expand access for regional patients.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-09-11
Description

BXPLANT co-hosted the 2025 Drug Development Strategy Course with KDRA's Bio Healthcare Talent Development Center. BXPLANT leadership served as instructors, providing training on clinical development strategy. KDRA and BXPLANT also offer free R&D, clinical development, and regulatory strategy consulting services for KDRA member companies.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-04-02
Description

BXPLANT co-hosted the 2025 Drug Development Strategy Course with KDRA's Bio Healthcare Talent Development Center. BXPLANT leadership served as instructors, providing training on clinical development strategy. KDRA and BXPLANT also offer free R&D, clinical development, and regulatory strategy consulting services for KDRA member companies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-31
Description

BXPLANT and Korea University Medical Center's academic-industry collaboration foundation signed an MOU for technology commercialization. The partnership aims to discover excellent technologies, facilitate R&D planning, identify demand companies for technology transfer, provide startup consulting, and support growth consulting across the full technology commercialization cycle. KU Medical Center has been designated as a research-focused hospital across all three campuses.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-02-13
Description

BXPLANT and ARKGEN BIOSCIONS signed an MOU for biopharmaceutical development collaboration. BXPLANT supports ARKGEN's biopharmaceutical development through preclinical and clinical development strategy formulation, global regulatory compliance, and clinical trial design and execution. ARKGEN focuses on multi-antibody therapeutics and cancer treatment vaccines. BXPLANT leverages its expertise to help ARKGEN pursue rapid and efficient development.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2024-12-23
Description

KDRA signed an MOU with DreamCIS, MediTip, and BXPLANT for full-cycle bio healthcare new drug development support. The partnership provides joint strategic consulting across early R&D, preclinical trials, regulatory affairs, clinical trials, business development, and investment for KDRA member companies. Additionally, the parties collaborate on developing strategic training programs for global market entry.

8PCMO - Public CDMO for Microbial-based Vaccines (미생물실증지원센터)
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2024-12-05
Description

BXPLANT and PCMO (a government-supported CDMO in Hwasun, Jeollanam-do established in 2017 with support from Ministry of Trade, Industry and Energy and Hwasun County) signed an MOU for full-cycle pharmaceutical development collaboration. BXPLANT combines its CDRO services with PCMO's manufacturing technology and production capabilities to accelerate Korea's bio industry and strengthen global market competitiveness. PCMO targets mRNA vaccine manufacturing facility completion in H1 2025.

bxplant.co.kr
9Woojung BIO (우정바이오)
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2024-09-04
Description

BXPLANT and Woojung BIO (preclinical testing specialist) co-hosted a seminar series on preclinical/clinical development strategies for successful new drug development. The second session focused on 'Establishing Proper Preclinical-Clinical Strategy for IND Approval.' BXPLANT CEO Heesun Kim served as speaker alongside researchers from KRIBB and Samsung Bioepis. PK/PD expertise spanning preclinical to clinical development was shared, with Woojung BIO providing open innovation opportunities to biotech companies.

bxplant.co.kr
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-26
Description

BXPLANT and Protium Science (a CDAO specialist and subsidiary of KOSDAQ-listed Tium Bio) signed a strategic partnership for CDMO and CDRO integration. The collaboration links CDAO & CDMO services with CDRO services, enabling integrated clinical development solutions for clients with advanced technologies. Protium Science provides biopharmaceutical production services from cell line development to API and finished drug product manufacturing, along with regulatory consulting.

Strategic tierMinorTypeOthersAnnounced on2024-03-26
Description

Bitrial Clinical Research is listed among BXPLANT's valued partner companies on the company homepage.

Strategic tierMinorTypeOthersAnnounced on2024-03-14
Description

Lightning Health is listed among BXPLANT's valued partner companies on the company homepage.

Strategic tierMinorTypeOthersAnnounced on2024-03-14
Description

Arriello is listed among BXPLANT's valued partner companies on the company homepage.

Strategic tierMinorTypeOthersAnnounced on2024-03-13
Description

Alcura is listed among BXPLANT's valued partner companies on the company homepage. Alcura operates in the pharmaceutical/biotech services sector.

15Korea Biotechnology Industry Organization (KoreaBIO) (한국바이오협회)
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2024-02-01
Description

BXPLANT and KoreaBIO conducted a strategic member meeting and jointly organized the 'Bio Bridge' development boot camp. The collaboration focuses on supporting biotech companies with pre-clinical and clinical development strategies, providing 1:1 expert consulting and deep training on development strategy. KoreaBIO aims to leverage BXPLANT's expertise to serve as a more robust platform connecting startups with pharmaceutical companies, research institutions, and investment networks.

bxplant.co.kr
Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

Avanti is listed among BXPLANT's valued partner companies on the company homepage. Operates in the pharmaceutical/healthcare sector.

Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

CJ Bioscience is listed among BXPLANT's valued partner companies on the company homepage. CJ Bioscience is a Korean biotech company developing biosimilars and novel biologics.

Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

EpiBiotech is listed among BXPLANT's valued partner companies on the company homepage. EpiBiotech is a Korean biotech company focused on epigenetic therapeutics.

Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

Honeynaps is listed among BXPLANT's valued partner companies on the company homepage. Honeynaps is a Korean biotech company.

Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

Daiichi Sankyo is listed among BXPLANT's valued partner companies on the company homepage. Daiichi Sankyo is a global pharmaceutical company.

21Prestige Biopharma (프레스티지바이오파마)
Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

Prestige Biopharma is listed among BXPLANT's valued partner companies on the company homepage. Prestige Biopharma is a Singapore-based biopharmaceutical company.

bxplant.co.kr
Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

Poonglim Pharm is listed among BXPLANT's valued partner companies on the company homepage.

Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

Klotho Sciences is listed among BXPLANT's valued partner companies on the company homepage.

Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

CureVerse is listed among BXPLANT's valued partner companies on the company homepage.

Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

Curamis is listed among BXPLANT's valued partner companies on the company homepage.

26Kolon Life Science (코오롱생명과학)
Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

Kolon Life Science is listed among BXPLANT's valued partner companies on the company homepage.

bxplant.co.kr
Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

Kine Sciences is listed among BXPLANT's valued partner companies on the company homepage.

28Jiufarm (지유팜)
Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

Jiufarm is listed among BXPLANT's valued partner companies on the company homepage.

bxplant.co.kr
Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

JETEMA is listed among BXPLANT's valued partner companies on the company homepage. JETEMA is a Korean pharmaceutical company.

Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

ETU is listed among BXPLANT's valued partner companies on the company homepage.

Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

Yuhan Health is listed among BXPLANT's valued partner companies on the company homepage.

32Yuyu Pharma (유유제약)
Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

Yuyu Pharma is listed among BXPLANT's valued partner companies on the company homepage. Yuyu Pharma is a Korean pharmaceutical company.

bxplant.co.kr
33USB Global (유스바이오글로벌)
Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

USB Global is listed among BXPLANT's valued partner companies on the company homepage. USB Global is a Korean biotech company.

bxplant.co.kr
Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

Ozonbio is listed among BXPLANT's valued partner companies on the company homepage.

35Entwick (entwick)
Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

Entwick is listed among BXPLANT's valued partner companies on the company homepage.

bxplant.co.kr
36Epinod (에피노드)
Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

Epinod is listed among BXPLANT's valued partner companies on the company homepage.

bxplant.co.kr
Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

AIRS Medical is listed among BXPLANT's valued partner companies on the company homepage. AIRS Medical is a Korean medtech company.

Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

Animus Cure is listed among BXPLANT's valued partner companies on the company homepage.

Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

CSG Rejon is listed among BXPLANT's valued partner companies on the company homepage.

Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

Sirnagen is listed among BXPLANT's valued partner companies on the company homepage.

41Sobagen (소바젠)
Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

Sobagen is listed among BXPLANT's valued partner companies on the company homepage.

bxplant.co.kr
42BTSynergy (비티시너지)
Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

BTSynergy is listed among BXPLANT's valued partner companies on the company homepage.

bxplant.co.kr
43Berum (베름)
Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

Berum is listed among BXPLANT's valued partner companies on the company homepage.

bxplant.co.kr
Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

Remonex is listed among BXPLANT's valued partner companies on the company homepage.

Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

DKi is listed among BXPLANT's valued partner companies on the company homepage.

Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

Decasight is listed among BXPLANT's valued partner companies on the company homepage. Decasight is a Korean medtech company.

Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

Kangstem is listed among BXPLANT's valued partner companies on the company homepage. Kangstem is a Korean biotech company.

48SK Chemicals (SK-chemicals)
Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

SK Chemicals is listed among BXPLANT's valued partner companies on the company homepage. SK Chemicals is a Korean chemical and pharmaceutical company.

bxplant.co.kr
49Mazu (메쥬)
Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

Mazu is listed among BXPLANT's valued partner companies on the company homepage.

bxplant.co.kr
50BR Pharma (br-pharm)
Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

BR Pharma is listed among BXPLANT's valued partner companies on the company homepage.

bxplant.co.kr
51BXPLANT (비엑스플랜트) Co-founders: Minkeun Jo and Heesun Kim
Strategic tierCoreTypeOthersAnnounced on2024-01-01
Description

BXPLANT was co-founded in January 2024 by former Daewoong Pharmaceutical executives Minkeun Jo (CEO, business expert with Master's in Economics and Ph.D. in Business Administration, former Business Unit Director at Daewoong Consumer Healthcare and Head of Management Planning at Woojung BIO) and Heesun Kim (CEO, new drug development expert with Master's in Pharmacy and Ph.D. in Clinical Trial Design, former Clinical Development Director at NextBio Science, Director of Clinical/Regulatory Affairs at Inventage Lab, and Head of Clinical Development Center at Daewoong Pharmaceutical). The company operates as a Science to Business platform providing total clinical development services across the full new drug development cycle.

bxplant.co.kr
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global CRO and life sciences services leader with deep Korean operations. While IQVIA is far broader than BXPLANT, it competes for large pharma Phase 3 outsourcing and increasingly for biosimulation/MIDD work in Korea.

TypeDirect peer
Description

Korean CRO offering clinical operations, regulatory affairs, and pharmacovigilance. MediTip is a co-MOU partner with BXPLANT under KDRA and competes for similar biotech venture and small pharma clients in Korea.

TypeDirect peer
Description

Global leader in biosimulation and model-informed drug development (PBPK, PK/PD, QSP). BXPLANT positions its MIDD/PK-PD platform on the same scientific stack as Certara, though BXPLANT localizes it for Korean biotech ventures. Certara is listed among BXPLANT's partners but is simultaneously a competitor for MIDD consulting work.

TypeBroad incumbent
Description

Global mid-sized CRO focused on biotech and small pharma sponsors. Medpace represents the type of full-service biotech-focused CRO that BXPLANT could either compete with for Korean biotech clients or partner with for global trial execution.

TypeEmerging player
Description

German data-driven drug development decision support firm. Molecular Health is a BXPLANT partner that offers comparable analytics-enabled clinical strategy support, positioning it as a niche competitor in data-driven R&D strategy.

6Physiomics
TypeEmerging player
Description

UK-based computational biology and systems biology services firm providing PK/PD and QSP modeling. Physiomics is listed as a BXPLANT partner but performs overlapping biosimulation work for biotech clients, making it a partial competitor in the MIDD niche.

TypeDirect peer
Description

Korean CRO with comprehensive clinical development, biostatistics, and regulatory services. DreamCIS is a KDRA co-MOU partner with BXPLANT and competes directly for biotech venture clinical execution contracts in Korea.

TypeEmerging player
Description

US-listed biosimulation software and services firm offering PBPK, QSP, and PK/PD modeling platforms. Simulations Plus is a direct competitor for MIDD-oriented consulting engagements and represents the kind of vertically integrated platform BXPLANT's MIDD strategy could eventually be benchmarked against.

TypeDirect peer
Description

Mid-sized Korean CRO covering clinical operations, biometrics, regulatory affairs, and pharmacovigilance. LSK Global competes head-to-head with BXPLANT for biotech venture Phase 1-3 clinical trial contracts in Korea.

TypeDirect peer
Description

Korean CRO with full-service clinical development and bioequivalence offerings. C&R Research provides comparable Phase 1-4 clinical services, regulatory strategy, and biostatistics to Korean biotech and pharma clients.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

비엑스플랜트

Clinical Development Servicesbxplant.co.kr

BXPLANT (비엑스플랜트) is a Seoul-based CDRO and biotech scalerator founded in 2024 by former Daewoong Pharmaceutical executives, providing full-cycle clinical development, MIDD-based PK/PD modeling, regulatory affairs, and seed investment services to Korean biotech ventures, pharmaceutical companies, and medical device firms.

What 비엑스플랜트 does

BXPLANT (비엑스플랜트) is a privately held Clinical Development and Research Organization (CDRO) and biotech scalerator founded in January 2024 and headquartered in Seongdong-gu, Seoul, South Korea. The company operates as a 'Clinical Intelligence Agency' providing full-cycle new drug and medical device development services, spanning R&D strategy, preclinical support, clinical strategy and consulting, PK/PD Modeling & Simulation (MIDD), clinical trial operations, regulatory affairs, data management and biostatistics, pharmacovigilance, and commercialization/valuation strategy. Its core technical differentiator is a Model-Informed Drug Development (MIDD) platform combining PK/PD modeling, PBPK modeling, quantitative systems pharmacology (QSP), and population PK/PD analysis to predict clinical outcomes and optimize dose selection before trials start.

BXPLANT was co-founded by former Daewoong Pharmaceutical executives Minkeun Jo (Co-CEO, business strategy) and Heesun Kim (Co-CEO, clinical development), with a leadership team drawn from Korean pharma majors including Daewoong, Hanmi, Chong Kun Dang, Samsung BioLogics, and CJ. The company generates revenue through project-based professional services engagements billed per contract, with multi-year contracts targeted in the billions of KRW per engagement. A secondary revenue stream derives from its scalerator function, in which the company provides seed capital to biotech startups from a self-funded ~2 billion KRW investment pool and earns returns through portfolio growth and exits. BXPLANT is officially registered as a CRO with KoNECT (Korea National Enterprise for Clinical Trials).

The company targets four primary customer segments: biotech ventures and bio startups (primary), pharmaceutical companies, medical device companies, and academic medical centers/research hospitals. Named clients include Woojung BIO, ARKGEN BIOSCIONS, and Protium Science, alongside a 50+ partner ecosystem. BXPLANT reports surpassing 100 billion KRW in cumulative order volume and achieving break-even within approximately two years of founding, with an IPO targeted between 2026-2028 at a 20 billion KRW annual revenue threshold.

비엑스플랜트 firmographics

Firmographics
Name
비엑스플랜트
Legal name
BXPLANT Co., Ltd.
Website
https://bxplant.co.kr
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Short description
BXPLANT (비엑스플랜트) is a Seoul-based CDRO and biotech scalerator founded in 2024 by former Daewoong Pharmaceutical executives, providing full-cycle clinical development, MIDD-based PK/PD modeling, regulatory affairs, and seed investment services to Korean biotech ventures, pharmaceutical companies, and medical device firms.
Ownership category
akta.pro rank

비엑스플랜트 industry classification

Industry
Product category
Clinical Development Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAEAJ
Companion Diagnostics (CDx) Development & Trial Testing Support
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Clinical development services
  • Contract research organization
  • Drug development consulting
  • Regulatory affairs services
  • Biotech venture acceleration

Where 비엑스플랜트 is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices1 record

Markets served

비엑스플랜트 business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. CDRO Clinical Development Services: Full-cycle new drug development services spanning preclinical consulting, clinical strategy, regulatory affairs (RA), CMC, preclinical toxicity studies, and Phase 1-4 clinical trial execution. Services are project-based and billed per engagement.
  2. Clinical Strategy Consulting: R&D strategy formulation, Target Product Profile (TPP) optimization, clinical development plan (CDP) design, regulatory pathway optimization, and gap analysis for biotech ventures and pharmaceutical companies. Project-based consulting fees.
  3. Investment / Scalerator Business: Identifying promising biotech startups, providing seed capital alongside strategic guidance, facilitating investment attraction, and supporting scale-up through fund formation and follow-up support programs. Investment returns from portfolio company growth and exits.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based engagements for biotech ventures, pharmaceutical companies, and medical device companies

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

비엑스플랜트 product offering

Product offering

Core offering

BXPLANT is a CDRO (Clinical Development and Research Organization) and biotech scalerator that delivers full-cycle new drug and medical device development services spanning R&D strategy, preclinical-to-clinical translation via MIDD/PK-PD modeling, clinical trial design and operations, regulatory affairs, and commercialization/out-licensing support. The company also operates a scalerator model, providing seed capital and growth acceleration to promising biotech startups alongside its consulting and CRO services.

Product overview

BXPLANT operates as a Clinical Intelligence Agency and CDRO (Clinical Development and Research Organization) company providing a unified platform of consulting and clinical services spanning the full new drug and medical device development lifecycle. The portfolio is organized into four core service pillars — Development & Strategic Solutions (non-clinical R&D support, PK/PD Modeling & Simulation, Clinical Strategy & Consulting, and CPL Services), Clinical Research Services (Medical Affair & Writing, Clinical Operations, Data Management & Biostatistics, and Pharmacovigilance), Regulatory Affairs, and Commercialization & Valuation Strategy — complemented by six specialized expertise areas: Chemical Drugs & Biologics, Advanced Therapy Products (ATMP), Medical Devices, In Vitro Diagnostics, Post-Market Surveillance & Pharmacovigilance, and Clinical Performance & Evaluation. The company also functions as a Scalerator, identifying and accelerating promising bio healthcare startups through investment, open innovation, and growth support. Revenue is derived from consulting services and CRO contract execution, with the company targeting IPO between 2026-2028.

Differentiator

Problem solved

Functional benefit

Products and services

  • Development & Strategic Solutions Tailored R&D portfolio management and asset valuation service for early development and innovation, combining non-clinical R&D support, PK/PD Modeling & Simulation, clinical strategy & consulting, and Clinical Project Lead (CPL) services. Designed for biotech ventures and pharmaceutical companies seeking to optimize go/no-go decisions, dose selection, and clinical strategy from preclinical through Phase 2 POC.
  • Clinical Research Services End-to-end CRO support for all-phase clinical trials covering Medical Affair & Writing, Clinical Operations, Data Management & Biostatistics (DM/STAT), and Pharmacovigilance & Post-Market Safety. Supports pharmaceuticals, biologics, medical devices, and IVDs across clinical and post-market phases with GCP compliance and audit/inspection readiness.
  • Regulatory Affairs Comprehensive regulatory strategy service from IND to marketing authorization, including CTD Module authoring, global submission readiness, and lifecycle regulatory consulting. Covers conventional and expedited pathways with local and global expertise for pharmaceuticals, biologics, medical devices, and IVDs.
  • Commercialization & Valuation Strategy Venture scalerating and growth acceleration service including portfolio assessment, venture discovery & investment, clinical development support, out-licensing strategy, and exit planning. Provides biotech startups with seed capital alongside strategic guidance, facilitating investment attraction, fund formation, and global expansion support.

Quantifiable outcome

  • Surpassed 100 billion KRW in order volume within ~2 years of establishment (2024-2026)
  • +3 more outcomes

Companies that use 비엑스플랜트

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

비엑스플랜트 technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

비엑스플랜트 partnerships and signals

Strategic signal

Partnerships

51 partnerships are on record, tiered core, strategic and minor.

  • Seoul Biohub (서울바이오허브)coreStrategic or Co-development Partner · 2 February 2026BXPLANT serves as the strategic accelerator for the '2026 Seoul Biohub X SK Biopharm Open Innovation' program, leading the entire process of identifying and nurturing promising companies. BXPLANT integrates its clinical and strategic expertise to provide intensive support so that SK Biopharm and innovative startups can achieve tangible results. The program recruits startups within 8 years of establishment to leverage SK Biopharm's drug development expertise and research infrastructure.
  • Kyungpook National University Hospital Clinical Trial Center (경북대학교병원 임상시험센터)coreStrategic or Co-development Partner · 7 January 2026BXPLANT and Kyungpook National University Hospital's Clinical Trial Center and Advanced Clinical Trial Center signed an MOU for strategic cooperation in clinical trial and clinical development. The partnership provides BXPLANT's CDRO-based services (clinical development strategy, trial design and operations, project management) alongside the hospital's medical staff, patient recruitment networks, and clinical infrastructure. The goal is to enable global-level clinical trial performance outside the Seoul metropolitan area and expand access for regional patients.
  • KDRA - Korea Drug Development Research Association (한국신약개발연구조합)strategicStrategic or Co-development Partner · 11 September 2025BXPLANT co-hosted the 2025 Drug Development Strategy Course with KDRA's Bio Healthcare Talent Development Center. BXPLANT leadership served as instructors, providing training on clinical development strategy. KDRA and BXPLANT also offer free R&D, clinical development, and regulatory strategy consulting services for KDRA member companies.
  • KDRA Bio Healthcare Talent Development Center (KDRA 바이오헬스 인재개발센터)strategicStrategic or Co-development Partner · 2 April 2025BXPLANT co-hosted the 2025 Drug Development Strategy Course with KDRA's Bio Healthcare Talent Development Center. BXPLANT leadership served as instructors, providing training on clinical development strategy. KDRA and BXPLANT also offer free R&D, clinical development, and regulatory strategy consulting services for KDRA member companies.
  • Korea University Medical Research & Business Foundation (고려대학교 의료원산학협력단)coreStrategic or Co-development Partner · 31 March 2025BXPLANT and Korea University Medical Center's academic-industry collaboration foundation signed an MOU for technology commercialization. The partnership aims to discover excellent technologies, facilitate R&D planning, identify demand companies for technology transfer, provide startup consulting, and support growth consulting across the full technology commercialization cycle. KU Medical Center has been designated as a research-focused hospital across all three campuses.
  • ARKGEN BIOSCIONS (아크젠바이오사이온스)strategicStrategic or Co-development Partner · 13 February 2025BXPLANT and ARKGEN BIOSCIONS signed an MOU for biopharmaceutical development collaboration. BXPLANT supports ARKGEN's biopharmaceutical development through preclinical and clinical development strategy formulation, global regulatory compliance, and clinical trial design and execution. ARKGEN focuses on multi-antibody therapeutics and cancer treatment vaccines. BXPLANT leverages its expertise to help ARKGEN pursue rapid and efficient development.
  • KDRA - Korea Drug Development Research Association (한국신약개발연구조합)strategicStrategic or Co-development Partner · 23 December 2024KDRA signed an MOU with DreamCIS, MediTip, and BXPLANT for full-cycle bio healthcare new drug development support. The partnership provides joint strategic consulting across early R&D, preclinical trials, regulatory affairs, clinical trials, business development, and investment for KDRA member companies. Additionally, the parties collaborate on developing strategic training programs for global market entry.
  • PCMO - Public CDMO for Microbial-based Vaccines (미생물실증지원센터)strategicStrategic or Co-development Partner · 5 December 2024BXPLANT and PCMO (a government-supported CDMO in Hwasun, Jeollanam-do established in 2017 with support from Ministry of Trade, Industry and Energy and Hwasun County) signed an MOU for full-cycle pharmaceutical development collaboration. BXPLANT combines its CDRO services with PCMO's manufacturing technology and production capabilities to accelerate Korea's bio industry and strengthen global market competitiveness. PCMO targets mRNA vaccine manufacturing facility completion in H1 2025.
  • Woojung BIO (우정바이오)strategicStrategic or Co-development Partner · 4 September 2024BXPLANT and Woojung BIO (preclinical testing specialist) co-hosted a seminar series on preclinical/clinical development strategies for successful new drug development. The second session focused on 'Establishing Proper Preclinical-Clinical Strategy for IND Approval.' BXPLANT CEO Heesun Kim served as speaker alongside researchers from KRIBB and Samsung Bioepis. PK/PD expertise spanning preclinical to clinical development was shared, with Woojung BIO providing open innovation opportunities to biotech companies.
  • Protium Science (프로티움사이언스)coreStrategic or Co-development Partner · 26 March 2024BXPLANT and Protium Science (a CDAO specialist and subsidiary of KOSDAQ-listed Tium Bio) signed a strategic partnership for CDMO and CDRO integration. The collaboration links CDAO & CDMO services with CDRO services, enabling integrated clinical development solutions for clients with advanced technologies. Protium Science provides biopharmaceutical production services from cell line development to API and finished drug product manufacturing, along with regulatory consulting.
  • Bitrial Clinical ResearchminorOthers · 26 March 2024Bitrial Clinical Research is listed among BXPLANT's valued partner companies on the company homepage.
  • Lightning HealthminorOthers · 14 March 2024Lightning Health is listed among BXPLANT's valued partner companies on the company homepage.
  • ArriellominorOthers · 14 March 2024Arriello is listed among BXPLANT's valued partner companies on the company homepage.
  • AlcuraminorOthers · 13 March 2024Alcura is listed among BXPLANT's valued partner companies on the company homepage. Alcura operates in the pharmaceutical/biotech services sector.
  • Korea Biotechnology Industry Organization (KoreaBIO) (한국바이오협회)strategicStrategic or Co-development Partner · 1 February 2024BXPLANT and KoreaBIO conducted a strategic member meeting and jointly organized the 'Bio Bridge' development boot camp. The collaboration focuses on supporting biotech companies with pre-clinical and clinical development strategies, providing 1:1 expert consulting and deep training on development strategy. KoreaBIO aims to leverage BXPLANT's expertise to serve as a more robust platform connecting startups with pharmaceutical companies, research institutions, and investment networks.
  • Avanti (아벤티)minorOthers · 1 February 2024Avanti is listed among BXPLANT's valued partner companies on the company homepage. Operates in the pharmaceutical/healthcare sector.
  • CJ Bioscience (CJ바이오사이언스)minorOthers · 1 February 2024CJ Bioscience is listed among BXPLANT's valued partner companies on the company homepage. CJ Bioscience is a Korean biotech company developing biosimilars and novel biologics.
  • EpiBiotech (에피바이오텍)minorOthers · 1 February 2024EpiBiotech is listed among BXPLANT's valued partner companies on the company homepage. EpiBiotech is a Korean biotech company focused on epigenetic therapeutics.
  • Honeynaps ( honeynaps)minorOthers · 1 February 2024Honeynaps is listed among BXPLANT's valued partner companies on the company homepage. Honeynaps is a Korean biotech company.
  • Daiichi Sankyo (다이아치 sankyo)minorOthers · 1 February 2024Daiichi Sankyo is listed among BXPLANT's valued partner companies on the company homepage. Daiichi Sankyo is a global pharmaceutical company.
  • Prestige Biopharma (프레스티지바이오파마)minorOthers · 1 February 2024Prestige Biopharma is listed among BXPLANT's valued partner companies on the company homepage. Prestige Biopharma is a Singapore-based biopharmaceutical company.
  • Poonglim Pharm (풍림무약)minorOthers · 1 February 2024Poonglim Pharm is listed among BXPLANT's valued partner companies on the company homepage.
  • Klotho Sciences (클로토 사이언스)minorOthers · 1 February 2024Klotho Sciences is listed among BXPLANT's valued partner companies on the company homepage.
  • CureVerse (큐어버스)minorOthers · 1 February 2024CureVerse is listed among BXPLANT's valued partner companies on the company homepage.
  • Curamis (큐라미스)minorOthers · 1 February 2024Curamis is listed among BXPLANT's valued partner companies on the company homepage.
  • Kolon Life Science (코오롱생명과학)minorOthers · 1 February 2024Kolon Life Science is listed among BXPLANT's valued partner companies on the company homepage.
  • Kine Sciences (카인사이언스)minorOthers · 1 February 2024Kine Sciences is listed among BXPLANT's valued partner companies on the company homepage.
  • Jiufarm (지유팜)minorOthers · 1 February 2024Jiufarm is listed among BXPLANT's valued partner companies on the company homepage.
  • JETEMA (제테마)minorOthers · 1 February 2024JETEMA is listed among BXPLANT's valued partner companies on the company homepage. JETEMA is a Korean pharmaceutical company.
  • ETU (이튜)minorOthers · 1 February 2024ETU is listed among BXPLANT's valued partner companies on the company homepage.
  • Yuhan Health (유한건강생활)minorOthers · 1 February 2024Yuhan Health is listed among BXPLANT's valued partner companies on the company homepage.
  • Yuyu Pharma (유유제약)minorOthers · 1 February 2024Yuyu Pharma is listed among BXPLANT's valued partner companies on the company homepage. Yuyu Pharma is a Korean pharmaceutical company.
  • USB Global (유스바이오글로벌)minorOthers · 1 February 2024USB Global is listed among BXPLANT's valued partner companies on the company homepage. USB Global is a Korean biotech company.
  • Ozonbio (오즈온바이오)minorOthers · 1 February 2024Ozonbio is listed among BXPLANT's valued partner companies on the company homepage.
  • Entwick (entwick)minorOthers · 1 February 2024Entwick is listed among BXPLANT's valued partner companies on the company homepage.
  • Epinod (에피노드)minorOthers · 1 February 2024Epinod is listed among BXPLANT's valued partner companies on the company homepage.
  • AIRS Medical (airs-medical)minorOthers · 1 February 2024AIRS Medical is listed among BXPLANT's valued partner companies on the company homepage. AIRS Medical is a Korean medtech company.
  • Animus Cure (애니머스큐어)minorOthers · 1 February 2024Animus Cure is listed among BXPLANT's valued partner companies on the company homepage.
  • CSG Rejon (씨케이리제온)minorOthers · 1 February 2024CSG Rejon is listed among BXPLANT's valued partner companies on the company homepage.
  • Sirnagen ( sirnagen)minorOthers · 1 February 2024Sirnagen is listed among BXPLANT's valued partner companies on the company homepage.
  • Sobagen (소바젠)minorOthers · 1 February 2024Sobagen is listed among BXPLANT's valued partner companies on the company homepage.
  • BTSynergy (비티시너지)minorOthers · 1 February 2024BTSynergy is listed among BXPLANT's valued partner companies on the company homepage.
  • Berum (베름)minorOthers · 1 February 2024Berum is listed among BXPLANT's valued partner companies on the company homepage.
  • Remonex (레모넥스)minorOthers · 1 February 2024Remonex is listed among BXPLANT's valued partner companies on the company homepage.
  • DKi (dki)minorOthers · 1 February 2024DKi is listed among BXPLANT's valued partner companies on the company homepage.
  • Decasight (decasight)minorOthers · 1 February 2024Decasight is listed among BXPLANT's valued partner companies on the company homepage. Decasight is a Korean medtech company.
  • Kangstem (kangstem)minorOthers · 1 February 2024Kangstem is listed among BXPLANT's valued partner companies on the company homepage. Kangstem is a Korean biotech company.
  • SK Chemicals (SK-chemicals)minorOthers · 1 February 2024SK Chemicals is listed among BXPLANT's valued partner companies on the company homepage. SK Chemicals is a Korean chemical and pharmaceutical company.
  • Mazu (메쥬)minorOthers · 1 February 2024Mazu is listed among BXPLANT's valued partner companies on the company homepage.
  • BR Pharma (br-pharm)minorOthers · 1 February 2024BR Pharma is listed among BXPLANT's valued partner companies on the company homepage.
  • BXPLANT (비엑스플랜트) Co-founders: Minkeun Jo and Heesun KimcoreOthers · 1 January 2024BXPLANT was co-founded in January 2024 by former Daewoong Pharmaceutical executives Minkeun Jo (CEO, business expert with Master's in Economics and Ph.D. in Business Administration, former Business Unit Director at Daewoong Consumer Healthcare and Head of Management Planning at Woojung BIO) and Heesun Kim (CEO, new drug development expert with Master's in Pharmacy and Ph.D. in Clinical Trial Design, former Clinical Development Director at NextBio Science, Director of Clinical/Regulatory Affairs at Inventage Lab, and Head of Clinical Development Center at Daewoong Pharmaceutical). The company operates as a Science to Business platform providing total clinical development services across the full new drug development cycle.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

비엑스플랜트 competitors and assessment

Company assessment

Broad incumbents

  • IQVIA: Global CRO and life sciences services leader with deep Korean operations. While IQVIA is far broader than BXPLANT, it competes for large pharma Phase 3 outsourcing and increasingly for biosimulation/MIDD work in Korea.
  • Medpace: Global mid-sized CRO focused on biotech and small pharma sponsors. Medpace represents the type of full-service biotech-focused CRO that BXPLANT could either compete with for Korean biotech clients or partner with for global trial execution.

Direct peers

  • MediTip: Korean CRO offering clinical operations, regulatory affairs, and pharmacovigilance. MediTip is a co-MOU partner with BXPLANT under KDRA and competes for similar biotech venture and small pharma clients in Korea.
  • Certara: Global leader in biosimulation and model-informed drug development (PBPK, PK/PD, QSP). BXPLANT positions its MIDD/PK-PD platform on the same scientific stack as Certara, though BXPLANT localizes it for Korean biotech ventures. Certara is listed among BXPLANT's partners but is simultaneously a competitor for MIDD consulting work.
  • DreamCIS: Korean CRO with comprehensive clinical development, biostatistics, and regulatory services. DreamCIS is a KDRA co-MOU partner with BXPLANT and competes directly for biotech venture clinical execution contracts in Korea.
  • LSK Global Pharma Services: Mid-sized Korean CRO covering clinical operations, biometrics, regulatory affairs, and pharmacovigilance. LSK Global competes head-to-head with BXPLANT for biotech venture Phase 1-3 clinical trial contracts in Korea.
  • C&R Research: Korean CRO with full-service clinical development and bioequivalence offerings. C&R Research provides comparable Phase 1-4 clinical services, regulatory strategy, and biostatistics to Korean biotech and pharma clients.

Emerging players

  • Molecular Health: German data-driven drug development decision support firm. Molecular Health is a BXPLANT partner that offers comparable analytics-enabled clinical strategy support, positioning it as a niche competitor in data-driven R&D strategy.
  • Physiomics: UK-based computational biology and systems biology services firm providing PK/PD and QSP modeling. Physiomics is listed as a BXPLANT partner but performs overlapping biosimulation work for biotech clients, making it a partial competitor in the MIDD niche.
  • Simulations Plus: US-listed biosimulation software and services firm offering PBPK, QSP, and PK/PD modeling platforms. Simulations Plus is a direct competitor for MIDD-oriented consulting engagements and represents the kind of vertically integrated platform BXPLANT's MIDD strategy could eventually be benchmarked against.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

비엑스플랜트 social profiles

Digital presence

비엑스플랜트 financial estimates

Financial estimate

Revenue estimate

Valuation estimate

비엑스플랜트 leadership team

Management profile

Number of profiles

Profiles6 records

비엑스플랜트 funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

비엑스플랜트 M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 비엑스플랜트

What does 비엑스플랜트 do?

BXPLANT is a CDRO (Clinical Development and Research Organization) and biotech scalerator that delivers full-cycle new drug and medical device development services spanning R&D strategy, preclinical-to-clinical translation via MIDD/PK-PD modeling, clinical trial design and operations, regulatory affairs, and commercialization/out-licensing support. The company also operates a scalerator model, providing seed capital and growth acceleration to promising biotech startups alongside its consulting and CRO services.

Is 비엑스플랜트 a public or private company?

비엑스플랜트 is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was 비엑스플랜트 founded?

비엑스플랜트 was founded in 2024. It employs 1 to 10 people.

Where is 비엑스플랜트 based?

비엑스플랜트 is headquartered in Seoul, South Korea, in the Asia region.

How does 비엑스플랜트 make money?

Three revenue lines are on record. CDRO Clinical Development Services are the primary driver. The others are clinical Strategy Consulting and investment / Scalerator Business.

Who are 비엑스플랜트's main competitors?

Broad incumbents on record are IQVIA and Medpace. Direct peers are MediTip, Certara, DreamCIS, LSK Global Pharma Services and C&R Research. Emerging players are Molecular Health, Physiomics and Simulations Plus.

Does 비엑스플랜트 have an API?

No public API is recorded for 비엑스플랜트.

What industry is 비엑스플랜트 in?

비엑스플랜트's product category is Clinical Development Services. Its primary akta.pro industry code is HLAGAKAA, Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA), with a secondary code of HLAGAEAJ, Companion Diagnostics (CDx) Development & Trial Testing Support. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals